在当代综合风险评估中遗留的hERG研究数据 - 缓解协议和积极对照文章差异风险
Richard W Daniels1, James W Kramer1, Matthew M Abernathy2
1Charles River Laboratories, Cleveland Inc., Cleveland, OH, USA.
Journal of pharmacological and toxicological methods
|July 19, 2025
概括
使用人类以太基因相关基因 (hERG) 通道测试的常规心脏安全评估可能不需要重复. 研究表明,使用传统协议与更新的最佳实践相比,使用hERG安全边际或功效没有显著差异,特别是用terfenadine作为对照.
科学领域:
- 药理学和毒理学 药理学和毒理学
- 心血管安全心血管安全
- 药物开发 药物开发
背景情况:
- 人类以太基因相关基因 (hERG) 测定是评估药物诱导的心脏风险的标准.
- ICH S7B指南 (2005年) 要求进行GLP hERG研究,2022年问答引入"最佳实践"建议.
- "遗留协议"研究与"修订协议"最佳实践之间存在差异,导致数据可比性不确定.
研究的目的:
- 评估遗留和修订的hERG测定协议之间的差异是否需要重新测试化合物.
- 确定使用旧协议的先前hERG评估是否比当前的最佳实践不那么敏感.
- 在传统和修订的hERG测试协议下比较关键阳性对照的性能.
主要方法:
- 根据传统和修订的协议,对三种阳性对照物品 (多菲提利德,莫西弗洛克萨,丹塞) 的比较.
- 根据传统和修订的协议对特芬阿丁和锡萨普里德的测试.
- 分析了2002-2018年历史的特纳丁 (60nM) 数据 (n=3627) 与IC50和山坡数据的预测.
主要成果:
- 在两个协议下测试的三个阳性对照物品的汇总hERG安全边际中没有发现显著差异.
- 在传统和修订协议之间,聚合的hERG IC50特尔芬阿丁值在传统和修订协议之间是可比的,尽管随着修订协议的增加,变异性增加了.
- 历史的特纳丁抑制数据与根据两个协议的IC50和Hill斜率值得出的预测保持一致.
结论:
- 该研究得出的结论是,如果使用纳丁 (60nM) 作为阳性对照,根据遗留协议进行的hERG评估可能是不必要的.
- 调查结果表明,在使用特纳丁时,传统的hERG协议对当前的最佳实践建议提供了可比的敏感性.
- 这一分析支持继续使用历史hERG数据,减少对冗余药物安全测试的需求.
相关概念视频
Healthcare Associated Infections II: Preventive Measures
4.7K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
4.7K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
631
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
631
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Relative Risk
2.5K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.5K
Strategies for Assessing and Addressing Confounding
606
Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
606
Hazard Ratio
786
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
786


